CelLBxHealth plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 sys… Read more
Market Cap & Net Worth: CelLBxHealth plc (CLBX)
CelLBxHealth plc (LSE:CLBX) has a market capitalization of $37.28K (GBX306.40 Million) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #48196 globally and #1164 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CelLBxHealth plc's stock price GBX0.95 by its total outstanding shares 322528409 (322.53 Million).
CelLBxHealth plc Market Cap History: 2025 to 2026
CelLBxHealth plc's market capitalization history from 2025 to 2026. Data shows growth from $43.17K to $37.28K (0.00% CAGR).
CelLBxHealth plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CelLBxHealth plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CLBX by Market Capitalization
Companies near CelLBxHealth plc in the global market cap rankings as of March 18, 2026.
Key companies related to CelLBxHealth plc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #91 globally with a market cap of $176.18 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #154 globally with a market cap of $120.38 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.34 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #512 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.18 Billion | $470.00 |
| #154 | Danaher Corporation | NYSE:DHR | $120.38 Billion | $191.39 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.34 Billion | $586.37 |
| #512 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
CelLBxHealth plc Historical Marketcap From 2025 to 2026
Between 2025 and today, CelLBxHealth plc's market cap moved from $43.17K to $ 37.28K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX37.28K | -13.64% |
| 2025 | GBX43.17K | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of CelLBxHealth plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.28K USD |
| MoneyControl | $37.28K USD |
| MarketWatch | $37.28K USD |
| marketcap.company | $37.28K USD |
| Reuters | $37.28K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.